GO
Loading...

FDA panel backs Mannkind's 'Afrezza'

Wednesday, 2 Apr 2014 | 1:42 PM ET

Matthew Pfeffer, MannKind CFO, discusses the recommendation of an FDA panel to approve his company's inhaled insulin treatment "Afrezza."